SynthesisFrontiers in oncology2026
Risk of dry eye syndrome after radiotherapy for orbital tumors: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This systematic review aimed to investigate the risk of developing dry eye syndrome following radiotherapy for orbital tumors. This study aimed to provide insights for formulating radiotherapy suggestions for orbital tumors and preventing dry eye syndrome. Methods: This systematic review collected literature published in PubMed, EBSCO, and Web of Science prior to December 1,2025 concerning dry eye syndrome induced by radiotherapy for orbital tumors. 23 studies total 1,602 patients with orbital tumors were included across all studies. The review adhered to the PRISMA guidelines, with literature quality assessed using the Newcastle-Ottawa Scale (NOS) scale. All data analyses were conducted using Stata 17. Results: The overall prevalence of Dry Eye Syndrome (DES) after orbital radiotherapy was 31% (95% CI: 15-48%, P< 0.01), with high heterogeneity (I Conclusion: Radiotherapy for orbital tumors significantly increases the risk of DES. Although statistical interactions were not significant, trends suggest that older age, higher radiation dose, and shorter follow-up may elevate DES risk, underscoring the need for tailored monitoring and preventive care. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.